Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study

Bibliographic Details
Main Authors:	Sleijfer, S, Gorlia, T, Lamers, C, Burger, H, Blay, J-Y, Le Cesne, A, Scurr, M, Collin, F, Pandite, L, Marreaud, S, Hohenberger, P
Format:	Online
Language:	English
Published:	Nature Publishing Group 2012
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419967/

Similar Items

Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma The European Organisation for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study
by: Penel, N, et al.
Published: (2011)

Pazopanib for the treatment of soft-tissue sarcoma
by: Heudel, Pierre, et al.
Published: (2012)

Pazopanib: Approval for Soft-Tissue Sarcoma
by: Nguyen, Diana T., et al.
Published: (2013)

Pazopanib in the management of advanced soft tissue sarcomas
by: Cranmer, Lee D, et al.
Published: (2016)

Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib
by: Rajendra, Rajeev, et al.
Published: (2013)

The role of Pazopanib in Soft Tissue Sarcoma: A comprehensive review of the literature
by: Fotopoulos George, et al.
Published: (2015-09-01)

Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom
by: Amdahl, Jordan, et al.
Published: (2014)

Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience
by: Frezza, Anna Maria, et al.
Published: (2014)

Relationship of angiogenic and apoptotic activities in soft-tissue sarcoma
by: Win, Thin Thin, et al.
Published: (2014)

Clinical activity of pazopanib in metastatic extraosseous Ewing sarcoma
by: Steven Attia, et al.
Published: (2015-05-01)

Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma
by: Attia, Steven, et al.
Published: (2015)

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group.
by: Nielsen, O. S., et al.
Published: (1998)

Recurrent retroperitoneal soft tissue sarcoma showing drastic reduction after pazopanib administration accompanied by severe liver dysfunction
by: Kazuki Okubo, et al.
Published: (2018-09-01)

Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis
by: Nakano, Kenji, et al.
Published: (2016)

Fatal hemorrhage in a patient with advanced soft tissue sarcoma following radiation and pazopanib treatment: A case report
by: KAWASAKI, KENTA, et al.
Published: (2016)

Metastatic Alveolar Soft Part Sarcoma Responsive to Pazopanib after Progression through Sunitinib and Bevacizumab: Two Cases
by: Read, William L., et al.
Published: (2016)

Expressions of angiogenic markers and apoptotic markers in soft tissue sarcoma
by: Yusuf, Yusri
Published: (2010)

Structured myeloid cells and anti-angiogenic therapy in alveolar soft part sarcoma
by: Castelli, Chiara, et al.
Published: (2013)

Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS)
by: Ronellenfitsch, Ulrich, et al.
Published: (2016)

Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy
by: Necchi, A, et al.
Published: (2014)

International clinical trials setting for rare cancers: organisational and regulatory constraints—the EORTC perspective
by: Shash, Emad, et al.
Published: (2013)

The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study
by: Nakamura, Tomoki, et al.
Published: (2016)

BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells
by: Kim, Hee Kyung, et al.
Published: (2016)

A randomized, double-blind, placebo-controlled, Phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup
by: Kawai, Akira, et al.
Published: (2016)

Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series
by: Yoo, Kwai Han, et al.
Published: (2015)

Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series
by: Verschoor, Arie J, et al.
Published: (2014)

Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma
by: Bally, Olivia, et al.
Published: (2015)

Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma—a suitable treatment option: case report and review of anti-angiogenic treatment options
by: Semenisty, Valeriya, et al.
Published: (2015)

Pazopanib and anti-VEGF therapy
by: Drabkin, Harry A
Published: (2010)

Activity of cytokine-induced killer cells against bone and soft tissue sarcoma
by: Sangiolo, Dario, et al.
Published: (2014)

Phase I trial of concurrent sunitinib and radiation therapy as preoperative treatment for soft tissue sarcoma
by: Jakob, Jens, et al.
Published: (2013)

The VEGF- and PDGF-family of angiogenic markers have prognostic impact in soft tissue sarcomas arising in the extremities and trunk
by: Kilvaer, Thomas K, et al.
Published: (2014)

Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma
by: Canter, Robert J, et al.
Published: (2014)

The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets
by: Rocchi, Laura, et al.
Published: (2014)

The cardiovascular profile and pharmacology of vandetanib and pazopanib
by: Carter, Joanne
Published: (2017)

Pazopanib-Induced Severe Acute Pancreatitis
by: Kawakubo, Kazumichi, et al.
Published: (2015)

Pazopanib-Induced Alopecia, an Underestimated Toxicity?
by: Biondo, Andrea, et al.
Published: (2015)

Pazopanib induced hand-foot syndrome
by: Sundriyal, Deepak, et al.
Published: (2015)

Combined sunitinib and radiation therapy for preoperative treatment of soft tissue sarcoma: results of a phase I trial of the German interdisciplinary sarcoma group (GISG-03)
by: Jakob, Jens, et al.
Published: (2016)

Combination of Trabectedin and Gemcitabine for Advanced Soft Tissue Sarcomas: Results of a Phase I Dose Escalating Trial of the German Interdisciplinary Sarcoma Group (GISG)
by: Kasper, Bernd, et al.
Published: (2015)